舒和颗粒治疗类风湿关节炎合并纤维肌痛慢性疼痛的随机双盲安慰剂对照预试验
本研究为随机双盲安慰剂对照预试验,纳入30例类风湿关节炎(RA)合并纤维肌痛(FM)患者,1:1分配至舒和颗粒(SHG)组或安慰剂组,每日两次治疗4周并随访8周。主要结局为视觉模拟量表(VAS)疼痛强度变化。线性混合效应模型显示VAS、PGA、PhGA、TJC的组×时间交互作用显著(P<0.001),SHG组VAS在第4周有临床意义下降(P<0.001),安慰剂组无显著变化。结论提示SHG可能短期减轻疼痛并改善功能、睡眠、疲劳及心理状态,安全性可接受,但需更大样本验证。
要点
- 舒和颗粒治疗4周可显著降低RA合并FM患者VAS疼痛评分(P<0.001),安慰剂组无显著变化。
- SHG组在PGA、PhGA、TJC及FM相关SSS、PHQ-9上显示显著组×时间交互作用(P<0.001)。
- 疲劳(FSS)和失眠(ISI)组内改善但组间差异无统计学意义,无严重不良事件。
核心结论
- 舒和颗粒可能为RA合并FM患者提供短期疼痛缓解及身体功能、睡眠、疲劳和心理健康的改善,安全性特征与安慰剂相当,但需更大规模多中心试验确认。
研究设计与样本
- 随机、双盲、安慰剂对照预试验,30例诊断为RA合并FM的患者按1:1随机分配至舒和颗粒组(n=15)或安慰剂组(n=15),每日两次治疗4周,随后随访8周。
- 主要结局为VAS疼痛强度变化;次要结局包括PGA、PhGA、TJC、SJC、WPI、SSS、FIQ、疲劳、睡眠质量、焦虑和抑郁评估;安全性通过不良事件记录和实验室检查监测。
主要发现
- 线性混合效应模型显示VAS(P<0.001)、PGA和PhGA(P<0.001)、TJC(P<0.001)的组×时间交互作用显著。
- SHG组VAS在第4周有临床意义下降(P<0.001),安慰剂组同期无显著变化;SHG组TJC改善持续至第8周(P<0.001)。
- FM相关结局中,SSS(P<0.001)和PHQ-9(P<0.001)的组×时间交互作用显著,SHG组SSS在第4周达临床意义改善(P<0.001),PHQ-9显著下降(P<0.001)。
- FSS和ISI组内改善但组间差异无统计学意义;无严重不良事件,所有参与者实验室参数在正常范围内。
关键数值与推荐
- 疼痛强度采用VAS评估,主要结局为VAS变化。
- FM特异性指标包括WPI、SSS、FIQ;心理评估包括PHQ-9;疲劳采用FSS,睡眠采用ISI。
- SHG组VAS第4周较基线有临床意义下降(P<0.001);SSS第4周达临床意义改善(P<0.001);PHQ-9显著降低(P<0.001)。
临床怎么用
- 对于RA合并FM的慢性疼痛患者,可考虑在常规治疗基础上短期试用舒和颗粒以缓解疼痛和改善多维症状。
- 治疗期间需监测VAS、TJC、SSS、PHQ-9等指标,关注疼痛及心理状态变化。
- FSS和ISI的组间差异不显著,对疲劳和失眠的疗效尚需进一步验证。
局限性
- 随访时间较短(治疗4周,随访8周),长期疗效和安全性未确定。
- 安慰剂组脱失较多(完成11例),可能影响结果解释。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with rheumatoid arthritis (RA) and concomitant fibromyalgia (FM) frequently experience severe, refractory pain, elevated disease activity scores, and substantial psychological distress. Conventional treatments frequently fail to adequately address this complex pain syndrome, and evidence-based traditional Chinese medicine (TCM) interventions for this specific comorbidity remain limited. This pilot study aimed to assess the feasibility of a definitive trial and preliminarily evaluate the efficacy and safety of Shuhe granules (SHG), a Chinese herbal formulation, for alleviating chronic pain and associated multidimensional symptoms in this patient population. METHODS: In this randomized, double-blind, placebo-controlled pilot trial, 30 patients diagnosed with both RA and FM were randomly assigned (1:1) to receive either SHG (n = 15) or matching placebo (n = 15) twice daily for 4 weeks, followed by an 8-week follow-up. The primary outcome was the change in pain intensity measured by visual analog scale (VAS). Secondary outcomes included patient and physician global assessments (PGA, PhGA), tender and swollen joint counts (TJC, SJC), FM-specific measures (WPI, SSS, FIQ), and assessments of fatigue, sleep quality, anxiety, and depression. Safety was monitored through adverse event recording and laboratory tests. RESULTS: Twenty-six patients completed the trial (placebo completers n = 11 vs. SHG n = 15). Linear mixed-effects models showed significant group × time interactions for VAS (P < 0.001), PGA and PhGA (P < 0.001), and TJC (P < 0.001). Within the SHG group, VAS scores showed a clinically meaningful reduction at week 4 (P < 0.001), while no significant change occurred in the placebo group during the same period. TJC improvements persisted to week eight in the SHG group (P < 0.001). For FM-related outcomes, significant group × time interactions were observed for SSS (P < 0.001) and PHQ-9 (P < 0.001), with the SHG group achieving clinically meaningful improvements in SSS at week 4 (P < 0.001) and significant reductions in PHQ-9 (P < 0.001). Although within-group improvements were also observed for FSS and ISI, between-group differences were not statistically significant. No serious adverse events occurred, and laboratory parameters remained within normal ranges for all participants. CONCLUSION: This pilot study provides preliminary evidence that SHG may offer short-term benefits in reducing pain and improving physical function, sleep, fatigue, and psychological wellbeing in patients with RA and comorbid FM, with a safety profile comparable to placebo. While these preliminary findings support the potential of SHG as a therapeutic option, they require confirmation in larger, multicenter trials with extended follow-up to establish definitive efficacy and explore underlying mechanisms. CLINICAL REHABILITATION IMPACT: SHG may represent a promising complementary therapy for relieving chronic pain and improving overall health in patients with RA complicated by FM. Larger, multicenter trials with extended follow-up are warranted to confirm these findings, explore underlying mechanisms, and define its role in integrative management strategies. CLINICAL TRIAL REGISTRATION: Chinese Clinical Trial Registry (ChiCTR), https://www.chictr.org.cn/showproj.html?proj=221912, Identifier ChiCTR2400081980.18 March 2024.
引用
- Yu YH, Li YX, Peng ML, et al. Effects of Shuhe granules on chronic pain in patients with rheumatoid arthritis and fibromyalgia: a randomized, double-blind, placebo-controlled trial. Front Pharmacol. 2026. PMID: 42158941. doi:10.3389/fphar.2026.1761852
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。